Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trilocked photodynamic senolytic inducer
- Development stage
- Preclinical
- Lead developer
- Hunan University
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
A trilocked photodynamic senolytic inducer (PDSI) is an experimental, liver-targeted, type-I photodynamic agent designed to selectively eliminate senescent cells for the treatment of liver fibrosis[1][5]. Upon activation by near-infrared (NIR) light, the trilocked PDSI produces superoxide anions (O2•–) within the lysosomes of senescent cells, triggering immunogenic necroptosis—a form of programmed cell death accompanied by immune activation. This process not only clears senescent cells but also enhances dendritic cell maturation and recruits cytotoxic T cells, potentiating further immune-mediated removal of senescent cells. The agent is further distinguished by its NIR fluorescence and photoacoustic imaging capabilities, allowing high-contrast, noninvasive visualization of senescent cells in vivo. Developed as a strategy for hepatic fibrosis resolution, the trilocked PDSI is preclinical and not yet in human clinical trials[1][5].
- Other names
- PDSI
02
Targets
GLB1 (Galactosidase Beta 1)
Beyond the preview
Go deeper on trilocked photodynamic senolytic inducer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trilocked photodynamic senolytic inducer.